Prognosis for renal cell carcinoma market development

Through 2021, small-molecule angiogenesis inhibitors will dominate the renal cell carcinoma (RCC) drug market. In 2011, this drug class held a 68% market share - this share will peak in 2017 at nearly 85%, according to a new report from health care advisory firm Decision Resources.

In 2021, the market share of small-molecule angiogenesis inhibitors will fall to 75%, owing to the generic erosion of some therapies in this class and to the launch of Bristol-Myers Squibb/Ono Pharmaceuticals’ novel immunotherapy, nivolumab.

The Pharmacor Renal Cell Carcinoma advisory service finds that, over the next decade, two new small-molecule angiogenesis inhibitors will launch for the treatment of advanced RCC (in addition to the 2012 launch of Pfizer’s Inlyta [axitinib]) – Aveo Oncology/Astellas Pharma/Kyowa Hakko Kirin’s tivozanib and Novartis’s dovitinib. In 2021, these agents will together capture 18% of RCC therapy sales.